TY - JOUR T1 - Effectiveness of Localized Lockdowns in the SARS-CoV-2 Pandemic JF - medRxiv DO - 10.1101/2020.08.25.20182071 SP - 2020.08.25.20182071 AU - Yige Li AU - Eduardo A. Undurraga AU - José R. Zubizarreta Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/09/06/2020.08.25.20182071.abstract N2 - Six months into the pandemic, non-pharmaceutical interventions (e.g., social distancing, lockdowns) are the only available measure to control severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) transmission. Around the world, policymakers have implemented localized lockdowns in small geographic areas to prevent the spread of the disease. As governments ease restrictions, localized lockdowns are becoming a relevant policy option in cases of resurgence, as they can, in principle, reduce social and economic costs compared to larger-scale SARS-CoV-2 suppression strategies. The effects of non-pharmaceutical interventions have been typically described using mathematical models; however, there is a lack of empirical evidence of their causal effects to inform health policy. Using an integrated dataset from Chile, we estimated the direct and indirect (spillover) causal effects of localized lockdowns on SARS-CoV-2 transmission. Our results show that the effectiveness of localized lockdowns is strongly modulated by duration and is affected by spillover effects from neighboring geographic areas. Our projections suggest that extending localized lockdowns will slow down the epidemic. However, by themselves, localized lockdowns will be unable to control epidemic growth due to spillovers from neighboring areas with high interdependencies, unless those contiguous areas also implement lockdowns.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was partially supported by a grant from the Alfred P. Sloan Foundation (G-2018-10118), an award from the Patient-Centered Outcomes Research Institute (PCORI; ME-2019C1-16172), and the ANID Millennium Science Initiative/ Millennium Initiative for Collaborative Research on Bacterial Resistance, MICROB-R, [NCN17_081]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Our research uses only publicly available data collected by the Chilean government; subjects cannot be identified directly or through identifiers. It is considered exempt by the Comite Etico Cientifico of Pontificia Universidad Catolica de Chile.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDatasets used and/or analyzed during the current study are available from Base de Datos CoVID-19 repository, Ministerio de Ciencia, Tecnologia, Conocimiento, e Innovacion. http://www.minciencia.gob.cl/covid19 ER -